Rivaroxaban with aspirin
Indication
Prevention of cardiac events in patients with coronary (CAD) or peripheral artery Disease (PAD) (NICE TA607)
NICE TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Green
Brand:
Xarelto®
Nice TA:
607
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
Rivaroxaban plus aspirin is recommended within its marketing authorisation, as an option for preventing atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease who are at high risk of ischaemic events.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: